Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaGünter U. Höglinger, Peter J. Nestor, Wolfgang H. Oertel et al.|Movement Disorders|2017Cited by 2.3k
Which ante mortem clinical features predict progressive supranuclear palsy pathology?Gesine Respondek, Carolin Kurz, Thomas Arzberger et al.|Movement Disorders|2017Cited by 163
The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forwardStéphane Lehéricy, David E. Vaillancourt, Klaus Seppi et al.|Movement Disorders|2017Cited by 119
GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibitionAlexander G. Murley, James B. Rowe, Matthew A Rouse et al.|Brain|2020Cited by 107
Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson’s diseaseClaire O’Callaghan, James B. Rowe, Frank H. Hezemans et al.|Brain|2021Cited by 97